CheckMate 77T: Nivolumab maintains quality of life and reduces symptom deterioration in resectable NSCLC
Reports and Proceedings
Updates every hour. Last Updated: 22-Dec-2025 03:11 ET (22-Dec-2025 08:11 GMT/UTC)
An analysis from the Phase 3 CheckMate 77T trial confirms that perioperative nivolumab does not compromise health-related quality of life (HRQoL) in patients with resectable non-small cell lung cancer (NSCLC), including those with Stage III N2 disease. These results were presented today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).
Triterpenes, a diverse family of plant-derived molecules, are increasingly recognized for their potential in medicine, food, and sustainable industry.
Nuclear medicine imaging, like (SPECT), scans the body’s interior to track organ function or detect disease. Current tools for nuclear medicine imaging are expensive and difficult to manufacture. New tool captures sharp, high-resolution signals of fine features at a fraction of the cost.